2024: GLP-1 Agonists Expand Beyond Diabetes (2024)
By 2024, GLP-1 receptor agonists—a drug class originally developed purely as glucose-lowering
agents for type 2 diabetes—had accumulated a body of trial evidence extending their clinical
utility to cardiovascular disease prevention, obesity management, heart failure, chronic kidney
disease, non-alcoholic steatohepatitis (MASH), obstructive sleep apnoea, and emerging data in
addiction, Parkinson's disease, and Alzheimer's disease. The breadth of benefit revealed GLP-1
receptors as a previously underappreciated node in systemic metabolic, inflammatory, and
neurological regulation.
The trajectory accelerated with several landmark trial readouts in 2023 and 2024. The SELECT
trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 %
in obese patients without diabetes, establishing weight loss-independent mechanisms of cardiac
protection. The FLOW trial showed that semaglutide 1 mg reduced kidney disease progression by
24 % in type 2 diabetes patients with chronic kidney disease. The SURMOUNT-OSA trial demonstrated
that tirzepatide—the dual GLP-1/GIP receptor agonist (Zepbound, Eli Lilly)—reduced apnoea-
hypopnoea index by up to 63 % in patients with moderate-to-severe obstructive sleep apnoea,
earning a new FDA indication in 2024.
Mechanistic research revealed that GLP-1 receptors are expressed in the heart, kidneys, liver,
lungs, brain, and immune cells, with receptor activation suppressing inflammatory cytokine
production (via NF-κB inhibition), reducing macrophage foam cell formation, promoting cardiac
myocyte survival, and activating dopaminergic reward circuits in ways that may reduce addictive
behaviours. Observational database studies reported lower rates of alcohol use disorder,
opioid misuse, and nicotine dependence in GLP-1 agonist users, prompting formal clinical trials.
The class's expansion transformed it from a $15 billion to a projected $150 billion+ market by
2030, with Novo Nordisk and Eli Lilly capturing over 90 % of GLP-1 revenue and achieving the
largest pharmaceutical market capitalisations in history.
เหตุใดสิ่งนี้จึงสำคัญ
The multi-indication expansion of GLP-1 agonists revealed a mechanistic pleiotropy—metabolic,
anti-inflammatory, cardiovascular, renal, and neurological—that fundamentally repositioned
the drug class from diabetes management to broad systemic medicine. It demonstrated that
molecular targets expressed across multiple organ systems can yield clinical benefits that only
emerge through large outcome trials, and established GLP-1 receptor pharmacology as a paradigm
for multi-organ disease modification.